The Lancet Neurology
Fecha de publicación: Novembre 2020
DOI: https://doi.org/10.1016/S1474-4422(20)30365-3
Autores: Jeremy D Isaacs, Marianne Boenink
Background: Dementia biomarkers are valuable research tools, providing glimpses of brain pathology and function previously only available from post-mortem investigations. Before large-scale adoption in clinical practice, however, these technologies should show that they contribute meaningfully, cost-effectively, and sustainably to patient care.
